IM
IMEXF.US Imagin Medical Inc
- Market cap
- USD 1.08K
- P/E
- -
- P/B
- 9.05x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2023.
Is IMEXF.US undervalued?
Graham numberThe Graham number of Imagin Medical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Imagin Medical Inc fundamental analysis
No fundamental analysis for Imagin Medical Inc yet.
Imagin Medical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Imagin Medical Inc
Imagin Medical Inc., a urologic oncology company, focuses on the research, development, and commercialization of medical devices in the bio-chemistry industry. It has a license agreement with Lawrence Livermore National Security, LLC to develop, manufacture, and sell a medical imaging device. The company is headquartered in Vancouver, Canada.
Full company profileImagin Medical Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Imagin Medical Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | - | - | 0.00 | -14.5K | -14.2K | -14.0K | -24.5K | -32.2K | -29.4K | -47.1K | -185K |
| Operating Income | -560K | -563K | -98.6K | -1.81M | -1.46M | -7.83M | -4.21M | -3.76M | -3.38M | -3.40M | -1.69M |
| EBITDA | -539K | -542K | -98.1K | -1.81M | -1.46M | -7.97M | -4.45M | -3.76M | -3.38M | -3.40M | -1.40M |
| Net Income | -493K | -2.01M | -403K | -2.26M | -1.54M | -7.96M | -4.46M | -4.38M | -11.5M | -2.49M | 1.79M |
| EPS | -2.54 | -10 | -8.97 | -1.68 | -0.63 | -1.48 | -0.64 | -0.53 | -1.27 | -0.25 | 0.17 |
| Balance Sheet | |||||||||||
| Total Assets | 2.29M | 301K | 41.5K | 351K | 390K | 6.17M | 2.49M | 219K | 775K | 1.35M | 1.12M |
| Total Liabilities | 53.2K | 74.2K | 217K | 225K | 901K | 180K | 382K | 550K | 12.3M | 14.7M | 13.1M |
| Shareholders' Equity | 2.23M | 227K | -176K | 126K | -511K | 5.99M | 2.11M | -331K | -11.5M | -13.3M | -12.0M |
| Cash & Short-term Investments | 943K | 272K | 29.5K | 72.8K | 246K | 5.82M | 2.27M | 27.6K | 266K | 40.3K | 22.2K |
| Total Debt | - | - | - | - | 100K | - | - | - | 11.7M | 13.5M | 11.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -404K | -456K | -256K | -1.40M | -664K | -4.63M | -4.04M | -4.11M | -4.09M | -2.63M | -931K |
| Capital Expenditure | 236K | 200K | 12.7K | 146K | 6.71K | 12.8K | 33.1K | 33.1K | 6.84K | 781K | 0.00 |
| Free Cash Flow | -640K | -657K | -269K | -1.55M | -671K | -4.64M | -4.07M | -4.15M | -4.10M | -3.41M | -931K |
| Ratios | |||||||||||
| ROE | -22.1% | -888.1% | - | -1,797.5% | - | -132.8% | -211.0% | - | - | - | - |
| ROA | -21.6% | -669.2% | -970.5% | -643.5% | -395.8% | -128.9% | -178.7% | -1,994.9% | -1,481.3% | -184.5% | 160.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Imagin Medical Inc dividends
Imagin Medical Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Oct 27, 2020.
Who owns Imagin Medical Inc
- Insiders 11.27%
- Institutions 0.00%
- Public & others 88.73%
- Shares outstanding 10.8M
- Free float 10.2M
Imagin Medical Inc company profile
- Company name
- Imagin Medical Inc
- Ticker
- IMEXF.US
- ISIN
- CA45250L1058
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- September
- Address
- 890 West Pender Street, Vancouver, BC, Canada, V6C 1L9
- Phone
- 833 246 2446
- Website
- imaginmedical.com
About Imagin Medical Inc
Imagin Medical Inc., a urologic oncology company, focuses on the research, development, and commercialization of medical devices in the bio-chemistry industry. It has a license agreement with Lawrence Livermore National Security, LLC to develop, manufacture, and sell a medical imaging device. The company is headquartered in Vancouver, Canada.
Imagin Medical Inc management
2- Mr. Edward James HutchensCEO, President & Director
- Mr. Michael G. VerganoDirector of Operations